Skip to main content

Table 5 Independent risk factors for MACE and death in the study population (multivariate analysis, A1A1 (n = 690), A1A2 (n = 248), A2A2 (n = 25))

From: Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting

 

MACE *

Death **

 

RR

95% CI

p

RR

95% CI

p

LVEF < 40%

2.07

1.37–3.13

0.001

2.81

1.53–5.16

0.001

Follow-up

      

   Beta-blocker no/yes

2.46

1.70–3.56

< 0.001

10.64

4.54–24.94

< 0.001

   ACE inhibitor no/yes

2.63

1.65–4.18

< 0.001

8.91

2.74–28.98

< 0.001

  1. * For MACE, Cox multivariable model included: hypercholesterolemia, coronary artery disease extent, LVEF, treatments during follow-up (statin and/or betablocker and/or ACE inhibitor), GP IIIa polymorphism. Other variables were not statistically significant in the univariate model.
  2. ** For death, Cox multivariable model included: age, hypercholesterolemia, past or current smoking, prior MI, family history of MI, coronary artery disease extent, LVEF, revascularisations during follow-up (PCI, CABG), treatment during follow-up (ACE inhibitor, betablocker, statin), GP IIIa polymorphism. Other variables were not statistically significant in the univariate model.
  3. ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft; CI, confidence interval; LVEF, left ventricular ejection fraction; MACE, major adverse coronary event; MI, myocardial infarction; PCI, percutaneous coronary intervention; RR, relative risk.
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us